ABBOTT PARK, Ill., June 16, 2015
/PRNewswire/ -- Abbott (NYSE: ABT) today confirmed its
continued support for Mylan N.V's growth strategy by stating
its intent to vote its 14.5 percent stake in Mylan in
favor of Mylan's proposed acquisition of Perrigo.
"We chose Mylan to acquire our developed markets branded
generics pharmaceuticals because its scale and breadth across
critical distribution channels, broad
and diverse portfolio, and commitment to patients
and product quality strongly positions it for
success in the years to come," said Miles
D. White, chairman and chief executive officer, Abbott. "As
both Mylan's largest shareholder and its partner
through our continued manufacturing relationships, Abbott has
considered the entire situation and we believe Mylan's standalone
strategy and acquisition of Perrigo will further enhance its
platform, is strategically compelling, value enhancing for
shareholders, and offers a clear path to completion. In light
of these factors, we will be voting in favor of the Perrigo
transaction."
About Abbott:
Abbott is a global healthcare company devoted to improving life
through the development of products and technologies that span the
breadth of healthcare. With a portfolio of leading, science-based
offerings in diagnostics, medical devices, nutritionals and branded
generic pharmaceuticals, Abbott serves people in more than 150
countries and employs approximately 73,000 people.
Visit Abbott at www.abbott.com and connect with us on Twitter at
@AbbottNews.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abbott-affirms-its-support-for-mylan-standalone-strategy-and-will-vote-its-mylan-shares-in-favor-of-mylans-proposed-acquisition-of-perrigo-300099799.html
SOURCE Abbott